MKI67 and colorectal carcinoma: Administration of various SSAs resulted in a reduction in tissue expression of proliferative antigens, i.e., Ki-67 in 4/12 patients with rectal cancer (RC) [101] and proliferating cell nuclear antigen (PCNA) in 6/10 patients with CRC versus control [102].